

Title (en)
METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I κ B KINASE (IKK)

Title (de)
VERFAHREN ZUR BEHANDLUNG VON ENTZÜNDUNGS- UND IMMUNKRANKHEITEN UNTER VERWENDUNG DER I KAPPA B-KINASE (IKK)

Title (fr)
METHODES DE TRAITEMENT DE MALADIES INFLAMMATOIRES ET IMMUNITAIRES A L'AIDE D'INHIBITEURS D'I KAPPA B KINASE (IKK)

Publication
EP 1363993 A4 20081112 (EN)

Application
EP 02714815 A 20020201

Priority

- US 0203060 W 20020201
- US 26585301 P 20010201
- US 96597701 A 20010927

Abstract (en)
[origin: WO02060386A2] The present invention describes methods of preventing and treating inflammatory and immune-related diseases or disorders using inhibitors of I kappa B kinase (IKK). Also described are IKK inhibitors effective for the prevention and treatment of inflammatory and immune-related diseases or disorders, as demonstrated in vivo. Further embodiments of the present invention relate to a specific IKK inhibitors, 4(2'-aminoethyl)amino- 1,8-dimethylimidazo(1,2-a) quinoxaline and compounds of formula (I), salts thereof, and pharmaceutical compositions.

IPC 1-7
C12N 1/21; C12N 5/10; C12N 9/12; C12N 15/54; C07D 487/04; A61K 31/4745; A61K 31/4985; A61K 31/519; A61P 29/00; A61P 37/00

IPC 8 full level
A61K 31/4985 (2006.01); **A61K 31/519** (2006.01); **A61K 38/22** (2006.01); **A61K 45/00** (2006.01); **A61P 1/04** (2006.01); **A61P 9/00** (2006.01); **A61P 9/02** (2006.01); **A61P 9/10** (2006.01); **A61P 11/00** (2006.01); **A61P 11/06** (2006.01); **C07D 487/04** (2006.01); **A61P 17/02** (2006.01); **A61P 17/04** (2006.01); **A61P 19/02** (2006.01); **A61P 25/00** (2006.01); **A61P 25/16** (2006.01); **A61P 25/28** (2006.01); **A61P 27/16** (2006.01); **A61P 29/00** (2006.01); **A61P 37/00** (2006.01); **A61P 37/06** (2006.01); **A61P 41/00** (2006.01); **A61P 43/00** (2006.01); **C12N 1/21** (2006.01); **C12N 15/54** (2006.01)

CPC (source: EP)
A61K 31/4745 (2013.01); **A61K 31/4985** (2013.01); **A61K 31/519** (2013.01); **A61P 1/04** (2018.01); **A61P 9/00** (2018.01); **A61P 9/02** (2018.01); **A61P 9/10** (2018.01); **A61P 11/00** (2018.01); **A61P 11/06** (2018.01); **A61P 17/02** (2018.01); **A61P 17/04** (2018.01); **A61P 19/02** (2018.01); **A61P 25/00** (2018.01); **A61P 25/16** (2018.01); **A61P 25/28** (2018.01); **A61P 27/16** (2018.01); **A61P 29/00** (2018.01); **A61P 37/00** (2018.01); **A61P 37/06** (2018.01); **A61P 41/00** (2018.01); **A61P 43/00** (2018.01); **Y02A 50/30** (2018.01)

Citation (search report)

- [E] WO 0228860 A2 20020411 - BRISTOL MYERS SQUIBB CO [US], et al
- [A] TSAI S -H ET AL: "Suppression of TNF[alpha]-mediated NF[kappa]B activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells", JOURNAL OF CELLULAR BIOCHEMISTRY 19990915 US, vol. 74, no. 4, 15 September 1999 (1999-09-15), pages 606 - 615, XP002497486, ISSN: 0730-2312

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

Designated extension state (EPC)
AL LT LV MK RO SI

DOCDB simple family (publication)
WO 02060386 A2 20020808; **WO 02060386 A3 20021010**; AU 2002247059 B2 20061116; CA 2436770 A1 20020808; CZ 20032287 A3 20040218; EP 1363993 A2 20031126; EP 1363993 A4 20081112; HU P0304045 A2 20040428; HU P0304045 A3 20050530; JP 2004529088 A 20040924; MX PA03006817 A 20031113; NO 20033429 D0 20030731; NO 20033429 L 20030924; PL 364111 A1 20041213

DOCDB simple family (application)
US 0203060 W 20020201; AU 2002247059 A 20020201; CA 2436770 A 20020201; CZ 20032287 A 20020201; EP 02714815 A 20020201; HU P0304045 A 20020201; JP 2002560582 A 20020201; MX PA03006817 A 20020201; NO 20033429 A 20030731; PL 36411102 A 20020201